Evogene Ltd. Share Price

EVGN

IL0011050551

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE 08:54:10 28/10/2026 pm IST			5-day change	1st Jan Change
117.90 ^ILa	+1.20%		+1.11%	-60.78%

28/10	Evogene Ltd. Announces Acute Graft-Versus-Host Disease As The Target Indication For Its Internal AI-Driven Drug Discovery Program	CI
07/10	Evogene Enters into Cooperation Agreement with L.I.A. Pure Capital	CI

Last Transcript: Evogene Ltd.

Evogene Ltd., Q2 2026 Earnings Call, Aug 18, 2026

18/08

More transcripts

Analysts' recommendations: Evogene Ltd.

02/23/02	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/23/18	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/21/29	Evogene : Aegis Capital Starts Evogene at Buy	MT
01/20/01	Evogene : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

More recommendations

News in other languages: Evogene Ltd.

24/04

La unidad Casterra de Evogene apuesta por el crecimiento del cultivo de ricino en Brasil

More news

Managers and Directors: Evogene Ltd.

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	01/12/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	01/01/2022

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	03/06/2010
Sarit Firon CHM	Chairman	60	01/06/2021

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD.	+1.20%	+1.11%	-71.81%	-94.13%	59.64L
WUXI APPTEC CO., LTD.	+0.65%	-3.36%	+36.98%	+60.50%	6.41TCr
ARGENX SE	+1.76%	+1.27%	+11.82%	+81.21%	5.55TCr
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+100.19%	5.3TCr
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	4.6TCr
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	4.25TCr
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	4.04TCr
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	3.23TCr
GENMAB A/S	+29.06%	+47.63%	+107.12%	+92.73%	3.45TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.99%	+0.22%	+24.00%	-10.18%	2.42TCr
Average	+3.64%	+3.78%	+39.99%	+136.41%	3.93TCr
Weighted average by Cap.	+3.38%	+3.49%	+49.26%	+159.68%

See all sector performances

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/26/28	ILA 117.90	+1.20%	66,763
26/26/26	ILA 116.50	+2.92%	73,987
23/26/23	ILA 113.20	-0.18%	8,560
22/26/22	ILA 113.40	-2.74%	57,453
21/26/21	ILA 116.60	-0.68%	54,691

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evogene Ltd.

Company calendar

Market Cap	59.64L 0 53.51L 49.47L 44.8L 83.7L 57Cr 84.71L 5.91Cr 2.36Cr 30Cr 2.24Cr 2.19Cr 94Cr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	59.64L 0 53.51L 49.47L 44.8L 83.7L 57Cr 84.71L 5.91Cr 2.36Cr 30Cr 2.24Cr 2.19Cr 94Cr	EV / Sales 2026 *	4.15x	EV / Sales 2027 *	2.29x
Free-Float	67.6%	Yield 2026 *	-	Yield 2027 *	-

28/10	Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program	PR
26/10	Evogene to Participate in Upcoming BIO-Europe in Germany and Drug Discovery Chemistry Europe in Spain	PR
20/10	Evogene to Participate in U.S. East Coast AI Drug Discovery Roadshow Organized by the Israel Export Institute and TradeIL	PR
07/10	Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors	PR
30/09	Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance	PR

1 day	+1.20%
1 week	+1.11%
Current month	-7.96%
1 month	-14.38%
3 months	-26.36%
6 months	-50.06%
Current year	-60.78%

1 week	111.8	125
1 month	110	149
Current year	110	410
1 year	110	427.9
3 years	110	3,700
5 years	110	8,980
10 years	110	33,500

Date	Insider	Type	Main position	Quantity	% Market Cap.
04/09/26	Nir Nimrodi	Free	Chairman	10,000	0.0754%
04/09/26	Leon Recanati	Other	Director	2,500	0.0189%
04/09/26	Adrian Percy	Free	Director	2,500	0.0189%

Evogene Ltd. Share Price

Stocks

EVGN

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd.

Chart: Evogene Ltd.

Latest news: Evogene Ltd.

Last Transcript: Evogene Ltd.

Analysts' recommendations: Evogene Ltd.

Press Releases: Evogene Ltd.

News in other languages: Evogene Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Evogene Ltd.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

Markets		Quality
TEL AVIV STOCK EXCHANGE	EVGN	Delayed
Nasdaq	EVGN	Delayed
CBOE	EVGN	Real-time

	2026 *	2027 *
Net sales	14.36L 0 12.88L 11.91L 10.79L 20.15L 14Cr 20.4L 1.42Cr 56.73L 7.16Cr 53.89L 52.75L 23Cr	26L 0 23.33L 21.57L 19.53L 36.49L 25Cr 36.93L 2.58Cr 1.03Cr 13Cr 97.57L 95.51L 41Cr
Net income	-1.22Cr -0 -1.09Cr -1.01Cr -91.42L -1.71Cr -115.9Cr -1.73Cr -12Cr -4.81Cr -61Cr -4.57Cr -4.47Cr -192.53Cr	-1.02Cr -0 -91.51L -84.61L -76.63L -1.43Cr -97Cr -1.45Cr -10Cr -4.03Cr -51Cr -3.83Cr -3.75Cr -161.38Cr
Net Debt	-	-